Cargando…
Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial
BACKGROUND: A large proportion of patients with T2DM in China do not meet accepted HbA1c targets despite the availability of guidelines that describe a treatment pathway for achieving glycemic control. The aim of this study is to identify the fasting plasma glucose (FPG) target that will provide the...
Autores principales: | Yang, Wenying, Yang, Zhaojun, Zhao, Jing, Lu, Hai, Luo, Tianhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037905/ https://www.ncbi.nlm.nih.gov/pubmed/27669747 http://dx.doi.org/10.1186/s13063-016-1588-6 |
Ejemplares similares
-
Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023) -
Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2)
por: Miura, Hiroshi, et al.
Publicado: (2018) -
INTERmittent FASTing in people with insulin‐treated type 2 diabetes mellitus – the INTERFAST‐2 study protocol
por: Obermayer, Anna, et al.
Publicado: (2022) -
The Mobile Insulin Titration Intervention (MITI) for Insulin Glargine Titration in an Urban, Low-Income Population: Randomized Controlled Trial Protocol
por: Levy, Natalie, et al.
Publicado: (2015) -
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)